Nancy G Klimas Selected Research

Chronic Fatigue Syndrome (Myalgic Encephalomyelitis)

1/2021	Sex-Based Differences in Plasma Autoantibodies to Central Nervous System Proteins in Gulf War Veterans versus Healthy and Symptomatic Controls.
9/2020	Using Plasma Autoantibodies of Central Nervous System Proteins to Distinguish Veterans with Gulf War Illness from Healthy and Symptomatic Controls.
1/2020	Unravelling myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): Gender-specific changes in the microRNA expression profiling in ME/CFS.
1/2019	Pharmaceutical Interventions in Chronic Fatigue Syndrome: A Literature-based Commentary.
1/2019	Genetic Predisposition for Immune System, Hormone, and Metabolic Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Pilot Study.
1/2017	Myalgic encephalomyelitis/chronic fatigue syndrome and gulf war illness patients exhibit increased humoral responses to the herpesviruses-encoded dUTPase: Implications in disease pathophysiology.
3/2016	Illness progression in chronic fatigue syndrome: a shifting immune baseline.
1/2016	Tracking post-infectious fatigue in clinic using routine Lab tests.
11/2014	Stress management skills, cortisol awakening response, and post-exertional malaise in Chronic Fatigue Syndrome.
5/2011	Immunological abnormalities as potential biomarkers in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Nancy G Klimas Research Topics

Disease

14	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 01/2021 - 03/2005
3	Irritable Bowel Syndrome (Syndrome, Irritable Bowel) 01/2021 - 01/2020
3	Inflammation (Inflammations) 01/2020 - 01/2004
3	Fatigue 01/2019 - 11/2012
2	Neuroinflammatory Diseases 01/2019 - 01/2018
2	Virus Diseases (Viral Diseases) 01/2003 - 01/2003
2	Infections 01/2003 - 01/2003
1	Genetic Predisposition to Disease (Genetic Predisposition) 01/2019
1	Pain (Aches) 01/2019
1	Wounds and Injuries (Trauma) 01/2019
1	Infectious Mononucleosis (Glandular Fever) 01/2016
1	Rheumatoid Arthritis 07/2015
1	Cushing Syndrome 01/2014
1	Acquired Immunodeficiency Syndrome (AIDS) 08/2008
1	Lymphocytosis 09/2005
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2004
1	Coronary Disease (Coronary Heart Disease) 01/2004
1	Hemophagocytic Lymphohistiocytosis (Hemophagocytic Syndrome) 11/2002

Drug/Important Bio-Agent (IBA)

10	Biomarkers (Surrogate Marker)IBA 01/2021 - 05/2010
3	Antiviral Agents (Antivirals)IBA 01/2019 - 01/2003
2	OrganophosphatesIBA 01/2019 - 01/2018
2	Isoflurophate (DFP)FDA Link 01/2019 - 01/2018
2	CytokinesIBA 01/2019 - 11/2009
2	Hormones (Hormone)IBA 01/2019 - 07/2015
2	Pharmaceutical PreparationsIBA 01/2019 - 01/2019
1	MicroRNAs (MicroRNA)IBA 01/2020
1	Immunoglobulins (Immunoglobulin)IBA 01/2020
1	Antidepressive Agents (Antidepressants)IBA 01/2019
1	CorticosteroneIBA 01/2019
1	DEET (DET)IBA 01/2019
1	Chlorpyrifos (Lorsban)IBA 01/2019
1	Pyridostigmine Bromide (Pyridostigmine)FDA LinkGeneric 01/2019
1	T-Cell Antigen Receptors (T-Cell Receptor)IBA 01/2019
1	SarinIBA 01/2019
1	Transforming Growth Factors (Transforming Growth Factor)IBA 01/2019
1	Tumor Necrosis Factor Receptors (Tumor Necrosis Factor Receptor)IBA 01/2019
1	dUTP pyrophosphataseIBA 01/2017
1	Immunosuppressive Agents (Immunosuppressants)IBA 07/2015
1	Hydrocortisone (Cortisol)FDA LinkGeneric 11/2014
1	Testosterone (Sustanon)FDA Link 01/2014
1	Neuropeptide YIBA 12/2010
1	Dipeptidyl Peptidase 4 (Dipeptidyl Peptidase IV)IBA 05/2010
1	Epinephrine (Adrenaline)FDA LinkGeneric 09/2005
1	Norepinephrine (Noradrenaline)FDA LinkGeneric 09/2005
1	Proteins (Proteins, Gene)FDA Link 03/2005
1	Protease Inhibitors (Protease Inhibitor)IBA 01/2004
1	Inflammation MediatorsIBA 01/2004
1	PerforinIBA 11/2002
1	AntibodiesIBA 11/2002

Therapy/Procedure

2	Highly Active Antiretroviral Therapy (HAART) 08/2008 - 01/2004
1	Therapeutics 07/2015